FDA Approves First Brain-Penetrating Therapy for Hunter Syndrome in Decades

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

A new treatment can now reach the brain to treat the severe neurological symptoms of a rare and devastating genetic disease called Hunter syndrome.

First brain-penetrating therapy.Previous treatments could not cross the blood-brain barrier, leaving neurological decline unchecked. This new drug directly targets the root cause in the brain, potentially slowing or preventing cognitive damage.
Addresses core disease symptom.Before now, there was no approved therapy for the neurological aspects of Hunter syndrome. AVLAYAH specifically treats the cognitive and central nervous system deterioration that defines the most severe form of the disease.
First new option in 20 years.Patients and families have had no new treatment alternatives for nearly two decades. This approval breaks a long therapeutic drought, providing renewed hope and a novel mechanism of action.
Accelerated FDA approval pathway.The FDA's expedited review recognized the urgent need for these patients. This allows critical access to the therapy years sooner than the standard approval process would typically allow.

The U.S. Food and Drug Administration has granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first new treatment for the neurologic symptoms of Hunter syndrome in nearly 20 years. This therapy is uniquely engineered to cross the blood-brain barrier, addressing a core and previously untreatable aspect of the devastating rare disease.

Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a genetic disorder where the lack of a specific enzyme causes harmful sugars to accumulate in cells throughout the body and brain. This leads to severe progressive damage, including cognitive decline, loss of mobility, and early death. Existing enzyme replacement therapies cannot reach the central nervous system, leaving the neurologic disease to advance unchecked. AVLAYAH is designed to solve this by fusing the needed enzyme with a proprietary TransportVehicle platform that binds to receptors and ferries the treatment across the blood-brain barrier.

The FDA's decision is based on compelling biomarker data from a Phase 1/2 clinical trial. The therapy demonstrated a 91% reduction in cerebrospinal fluid heparan sulfate, a key disease biomarker, after 24 weeks of treatment. Notably, 93% of treated patients saw their biomarker levels fall into the range observed in individuals without Hunter syndrome. This surrogate endpoint was deemed reasonably likely to predict clinical benefit, paving the way for accelerated approval while a confirmatory trial continues.

Broader Implications and Next Steps

Beyond its immediate impact for Hunter syndrome, the approval validates a novel scientific platform for delivering biologic drugs to the brain. This breakthrough could inform future treatments for a wide range of other neurodegenerative and lysosomal storage diseases. The FDA also awarded Denali Therapeutics a Rare Pediatric Disease Priority Review Voucher, an incentive for developing therapies for serious childhood illnesses.

The ongoing global Phase 2/3 COMPASS study is now crucial for verifying the clinical benefit of AVLAYAH and supporting full regulatory approval. The therapy, administered weekly, is expected to be available in the U.S. shortly. For families who have waited decades for an option that reaches the brain, this approval marks a pivotal shift from managing symptoms to potentially altering the course of neurologic disease.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.